A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

Open label, randomized, 2-period, multiple-dose crossover study. Approximately 86 healthy, adult male and female subjects will be enrolled. Subjects will be randomized to 1 of 2 treatment sequences prior to the first study product treatment in treatment period 1. For each treatment period; subjects will receive donepezil for 5 consecutive weeks. Blood samples for donepezil PK will be collected pre-dose through week 10. Adhesion and skin irritation will be monitored throughout TDS treatments. Safety will be monitored throughout the study by adverse event reporting, repeated clinical and laboratory evaluations.